GAIN THERAPEUTICS INC (GANX) Stock News

USA - NASDAQ:GANX - US36269B1052 - Common Stock

2.04 USD

+0.14 (+7.37%)

Last: 10/14/2025, 6:44:01 PM

1.94 USD

-0.1 (-4.9%)

After Hours: 10/14/2025, 6:44:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

GANX Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Gain Therapeutics, Inc.

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease

6 days ago - By: Gain Therapeutics, Inc.

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease

8 days ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®

8 days ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®

21 days ago - By: Gain Therapeutics, Inc.

Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025

21 days ago - By: Gain Therapeutics, Inc.

Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025

a month ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease

a month ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease

a month ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation

2 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update

2 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update

2 months ago - By: Benzinga - Mentions: XTLB ASMB MCRB SNES ...

12 Health Care Stocks Moving In Friday's After-Market Session

3 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference

3 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference

3 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering

3 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering

3 months ago - By: Benzinga - Mentions: CYCC LIXT CBIO RPTX ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

3 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Announces Proposed Public Offering

3 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Announces Proposed Public Offering

4 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation

4 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation

4 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics to Participate in Upcoming Investor Conferences

5 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

5 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

5 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

5 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

5 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders

5 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders

6 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics to Participate at The Citizens Life Sciences Conference

6 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics to Participate at The Citizens Life Sciences Conference

6 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders

6 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders

6 months ago - By: Yahoo Finance - Mentions: CNC GLRE AVAH DGX ...

Is Centene Corporation (CNC) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?

6 months ago - By: Yahoo Finance - Mentions: GLPG GLRE CNC COYA ...

Is Galapagos (GLPG) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?

6 months ago - By: Yahoo Finance - Mentions: TEVA GLRE MRVL OXY

Teva Pharmaceutical Industries (TEVA): Among the Top Healthcare Stocks to Buy According to Billionaire David Einhorn

6 months ago - By: Yahoo Finance - Mentions: COYA GLRE KC LOAR ...

Is Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?